Revolution Medicines Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 411

Employees

  • Stock Symbol
  • RVMD

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $38.21
  • (As of Friday Closing)

Revolution Medicines General Information

Description

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Contact Information

Website
www.revmed.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 700 Saginaw Drive
  • Redwood City, CA 94063
  • United States
+1 (415) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Revolution Medicines Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$38.21 $37.54 $15.44 - $41.20 $6.3B 165M 1.23M -$3.82

Revolution Medicines Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 3,542,961 3,947,337 1,525,184 1,277,836
Revenue 4,566 11,580 35,380 29,390
EBITDA (542,137) (477,761) (248,623) (180,676)
Net Income (484,272) (436,367) (248,705) (187,091)
Total Assets 1,908,362 2,061,705 811,930 737,988
Total Debt 88,029 87,944 64,205 66,633
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Revolution Medicines Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Revolution Medicines‘s full profile, request access.

Request a free trial

Revolution Medicines Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Revolution Medicines‘s full profile, request access.

Request a free trial

Revolution Medicines Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies t
Biotechnology
Redwood City, CA
411 As of 2024
00000
00000000 00000

000000

ulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 00000

000000

luptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000 000000000
Paris, France
00 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Revolution Medicines Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ImmunityBio Formerly VC-backed San Diego, CA 000 00000 000000000 00000
Valerio Therapeutics Formerly VC-backed Paris, France 00 00000 000000000 00000
Poseida Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 00000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Onconova Therapeutics Formerly VC-backed Newtown, PA 00 00000 00000000 00000
You’re viewing 5 of 41 competitors. Get the full list »

Revolution Medicines Patents

Revolution Medicines Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240082249-A1 Methods of treating cancer with an mtor inhibitor Pending 25-May-2022 0000000000
US-20240100056-A1 Methods of treating cancer with an mtor inhibitor Pending 25-May-2022 0000000000
EP-4227307-A1 Pyrazolopyrazine compounds as shp2 inhibitors Inactive 11-Feb-2022 0000000000 000
US-20230303591-A1 Ras inhibitors Pending 08-Oct-2021 0000000000
CA-3234100-A1 Ras inhibitors Pending 08-Oct-2021 C07D519/00
To view Revolution Medicines’s complete patent history, request access »

Revolution Medicines Executive Team (22)

Name Title Board Seat Contact Info
Mark Goldsmith Ph.D Chief Executive Officer & Chairman
Martin Burke Ph.D Scientific Founder
Stephen Kelsey MD President
Steve Kelsey MD President of Research & Development
Jack Anders Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
You’re viewing 5 of 22 executive team members. Get the full list »

Revolution Medicines Board Members (15)

Name Representing Role Since
Alexis Borisy Third Rock Ventures Board Member 000 0000
Barbara Weber MD Third Rock Ventures Board Member 000 0000
Elizabeth Anderson Revolution Medicines Board Member 000 0000
Eric Schmidt Ph.D Revolution Medicines Board Member 000 0000
Mark Goldsmith Ph.D Revolution Medicines Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 15 board members. Get the full list »

Revolution Medicines Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Revolution Medicines Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EQRx 09-Nov-2023 0000000000 00.000 Biotechnology 0000 0000
Warp Drive Bio 31-Jan-2019 Merger/Acquisition 0000 Drug Discovery 0000 0000
To view Revolution Medicines’s complete acquisitions history, request access »

Revolution Medicines ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

33.97 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view Revolution Medicines’s complete esg history, request access »

Revolution Medicines FAQs

  • When was Revolution Medicines founded?

    Revolution Medicines was founded in 2014.

  • Who is the founder of Revolution Medicines?

    Martin Burke Ph.D, Michael Fischbach Ph.D, Roger VanHoy, David Pompliano Ph.D, and Kevan Shokat Ph.D are the founders of Revolution Medicines.

  • Who is the CEO of Revolution Medicines?

    Mark Goldsmith Ph.D is the CEO of Revolution Medicines.

  • Where is Revolution Medicines headquartered?

    Revolution Medicines is headquartered in Redwood City, CA.

  • What is the size of Revolution Medicines?

    Revolution Medicines has 411 total employees.

  • What industry is Revolution Medicines in?

    Revolution Medicines’s primary industry is Biotechnology.

  • Is Revolution Medicines a private or public company?

    Revolution Medicines is a Public company.

  • What is Revolution Medicines’s stock symbol?

    The ticker symbol for Revolution Medicines is RVMD.

  • What is the current stock price of Revolution Medicines?

    As of 21-Jun-2024 the stock price of Revolution Medicines is $38.21.

  • What is the current market cap of Revolution Medicines?

    The current market capitalization of Revolution Medicines is $6.3B.

  • What is Revolution Medicines’s current revenue?

    The trailing twelve month revenue for Revolution Medicines is $4.57M.

  • Who are Revolution Medicines’s competitors?

    ImmunityBio, Valerio Therapeutics, Poseida Therapeutics, CytomX Therapeutics, and Onconova Therapeutics are some of the 41 competitors of Revolution Medicines.

  • What is Revolution Medicines’s annual earnings per share (EPS)?

    Revolution Medicines’s EPS for 12 months was -$3.82.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »